Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NASDAQ:LGND NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$17.69-1.6%$19.48$10.21▼$25.67$4.22B0.433.66 million shs2.35 million shsANIPANI Pharmaceuticals$66.60+4.1%$63.04$52.50▼$77.00$1.44B0.57318,264 shs571,065 shsLGNDLigand Pharmaceuticals$129.63+4.3%$110.23$90.29▼$130.68$2.50B0.84117,584 shs290,668 shsRGENRepligen$119.75+1.4%$125.01$102.97▼$182.52$6.73B1.11728,796 shs690,114 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-3.75%+0.95%-13.60%-15.31%+34.28%ANIPANI Pharmaceuticals-1.83%-1.64%+2.30%-7.51%+1.23%LGNDLigand Pharmaceuticals-2.06%+7.97%+10.49%+18.81%+28.58%RGENRepligen-2.66%-8.14%-7.39%-10.60%-3.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics3.8634 of 5 stars3.71.00.00.02.92.53.1ANIPANI Pharmaceuticals3.735 of 5 stars2.51.00.03.32.73.31.3LGNDLigand Pharmaceuticals4.0424 of 5 stars2.51.00.04.42.13.31.9RGENRepligen4.6309 of 5 stars4.31.00.04.52.31.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6756.40% UpsideANIPANI Pharmaceuticals 3.00Buy$78.8818.43% UpsideLGNDLigand Pharmaceuticals 3.00Buy$147.1713.53% UpsideRGENRepligen 2.69Moderate Buy$170.7542.59% UpsideCurrent Analyst Ratings BreakdownLatest LGND, ADMA, ANIP, and RGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$84.007/8/2025RGENRepligenEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$140.00 ➝ $130.006/24/2025RGENRepligenBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$150.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/8/2025ADMAADMA BiologicsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.005/5/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.004/30/2025RGENRepligenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$202.00 ➝ $189.004/29/2025RGENRepligenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$200.00 ➝ $190.004/29/2025RGENRepligenWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$160.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M9.90$0.51 per share34.51$1.48 per share11.95ANIPANI Pharmaceuticals$614.38M2.35$7.76 per share8.58$19.11 per share3.49LGNDLigand Pharmaceuticals$167.13M14.96$1.64 per share78.99$43.95 per share2.95RGENRepligen$634.44M10.60$3.07 per share39.05$35.21 per share3.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8520.8125.64N/A45.01%47.16%30.51%8/6/2025 (Estimated)ANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.82N/A-3.12%21.35%7.52%8/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A34.94N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)RGENRepligen-$25.51M-$0.45N/A50.743.47-3.93%4.53%3.17%7/29/2025 (Estimated)Latest LGND, ADMA, ANIP, and RGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A8/5/2025Q2 2025LGNDLigand Pharmaceuticals$1.54N/AN/AN/A$43.87 millionN/A7/29/2025Q2 2025RGENRepligen$0.40N/AN/AN/A$174.62 millionN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36ANIPANI Pharmaceuticals1.462.661.98LGNDLigand PharmaceuticalsN/A5.275.02RGENRepligen0.276.795.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%LGNDLigand Pharmaceuticals91.28%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%ANIPANI Pharmaceuticals12.70%LGNDLigand Pharmaceuticals7.00%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million229.90 millionOptionableANIPANI Pharmaceuticals60021.66 million18.91 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableRGENRepligen1,77856.18 million55.51 millionOptionableLGND, ADMA, ANIP, and RGEN HeadlinesRecent News About These CompaniesRepligen Corporation (NASDAQ:RGEN) Shares Acquired by Rice Hall James & Associates LLCJuly 15 at 5:45 AM | marketbeat.comRepligen (NASDAQ:RGEN) Trading Down 5.4% - Here's WhyJuly 14 at 2:04 PM | marketbeat.comTimesSquare Capital Management LLC Has $30.03 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)July 14 at 8:50 AM | marketbeat.comSlow Capital Inc. Has $4.18 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)July 14 at 7:10 AM | marketbeat.comNew York State Common Retirement Fund Grows Holdings in Repligen Corporation (NASDAQ:RGEN)July 14 at 5:23 AM | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Shares Bought by Stephens Investment Management Group LLCJuly 13 at 6:26 AM | marketbeat.comTeacher Retirement System of Texas Increases Stake in Repligen Corporation (NASDAQ:RGEN)July 11, 2025 | marketbeat.comBanque Pictet & Cie SA Has $3.12 Million Stock Position in Repligen Corporation (NASDAQ:RGEN)July 10, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Position in Repligen Corporation (NASDAQ:RGEN)July 9, 2025 | marketbeat.comRepligen And 2 Other Stocks That May Be Trading Below Estimated ValueJuly 8, 2025 | finance.yahoo.comEvercore ISI Cuts Repligen (NASDAQ:RGEN) Price Target to $130.00July 8, 2025 | marketbeat.comNew York State Teachers Retirement System Has $6.49 Million Holdings in Repligen Corporation (NASDAQ:RGEN)July 6, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 6, 2025 | americanbankingnews.comRepligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 6, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Shares Sold by Impax Asset Management Group plcJuly 5, 2025 | marketbeat.com1 Healthcare Stock to Target This Week and 2 to Be Wary OfJuly 3, 2025 | msn.comWCM Investment Management LLC Has $13.74 Million Stock Position in Repligen Corporation (NASDAQ:RGEN)July 3, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $3.98 Million Stake in Repligen Corporation (NASDAQ:RGEN)July 2, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Purchases 16,421 Shares of Repligen Corporation (NASDAQ:RGEN)June 30, 2025 | marketbeat.comWall Street Zen Downgrades Repligen (NASDAQ:RGEN) to HoldJune 29, 2025 | marketbeat.comArtemis Investment Management LLP Grows Position in Repligen Corporation (NASDAQ:RGEN)June 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGND, ADMA, ANIP, and RGEN Company DescriptionsADMA Biologics NASDAQ:ADMA$17.69 -0.29 (-1.61%) Closing price 04:00 PM EasternExtended Trading$18.13 +0.44 (+2.51%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$66.60 +2.60 (+4.06%) Closing price 04:00 PM EasternExtended Trading$66.62 +0.02 (+0.03%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Ligand Pharmaceuticals NASDAQ:LGND$129.63 +5.33 (+4.29%) Closing price 04:00 PM EasternExtended Trading$129.70 +0.06 (+0.05%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Repligen NASDAQ:RGEN$119.75 +1.65 (+1.40%) Closing price 04:00 PM EasternExtended Trading$121.84 +2.09 (+1.74%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
